PTPσ (receptor-type tyrosine-protein phosphatase sigma, encoded by PTPRS) has been identified as a key modifier of neurodegeneration in C9ORF72-associated Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). This discovery emerged from genome-wide CRISPRi screening in human neurons, revealing that PTPσ modulates disease progression through regulation of phosphatidylinositol 3-phosphate (PI3P) signaling. The finding represents a breakthrough in understanding the complex genetic architecture of ALS/FTD and identifies PTPσ as a novel therapeutic target with genetic validation from loss-of-function screening.
The C9ORF72 hexanucleotide repeat expansion is the most common genetic cause of ALS and FTD:
- Repeat expansion: GGGGCC repeat in the first intron
- Pathogenic mechanisms:
- Dipeptide repeat proteins (DPRs) — translation of repeat expansions into toxic poly-GA, poly-GP, poly-GR proteins
- RNA foci — repeat RNA sequesters RNA-binding proteins
- Loss of function — reduced C9ORF72 protein function affecting autophagy and endolysosomal trafficking
C9ORF72 mutations cause a continuum of diseases:
- ALS (50% of familial ALS)
- FTD (25% of familial FTD)
- ALS-FTD overlap syndrome
¶ Structure and Function
PTPσ (also known as PTPRS) is a receptor-type tyrosine phosphatase:
- Domain structure: Extracellular carbonic anhydrase-like domains, transmembrane region, cytoplasmic tyrosine phosphatase domain
- Expression: Primarily in nervous system — neurons and glia
- Physiological roles:
- Synapse formation and function
- Axon guidance
- Neuronal development
- Receptor tyrosine kinase signaling regulation
PTPσ plays critical roles in:
- Synaptic plasticity — modulates NMDA receptor signaling
- Axon regeneration — regulates growth cone dynamics
- Myelination — influences oligodendrocyte differentiation
- Glial scar formation — modulates astrocyte reactivity
Phosphatidylinositol 3-phosphate (PI3P) is a critical phospholipid signaling molecule:
- Cellular functions:
- Autophagosome formation and maturation
- Endosomal trafficking
- Membrane recruitment of autophagy proteins
- Vesicle trafficking
Dysregulated PI3P signaling contributes to:
- Impaired autophagy-lysosomal pathway
- Endosomal dysfunction
- Protein aggregation
- Synaptic degeneration
Genome-wide CRISPRi screening in human neurons identified PTPσ as a modifier of C9ORF72 toxicity:
- Screening approach: Genome-scale loss-of-function screen in iPSC-derived neurons
- Hit identification: PTPσ knockdown exacerbated C9ORF72 toxicity
- Validation: PTPσ overexpression protected against C9ORF72 toxicity
PTPσ modulates neurodegeneration through PI3P regulation:
flowchart TD
A["C9ORF72 hexanucleotide repeat<br/>expansion"] --> B["DPR aggregation<br/>RNA foci formation"]
B --> C["Endolysosomal<br/>dysfunction"]
C --> D["PI3P signaling<br/>dysregulation"]
E["PTPσ activity"] --> F["Phosphatase activity<br/>on RTK substrates"]
F --> G["PI3P levels<br/>modulation"]
G --> H["Autophagy<br/>enhancement"]
H --> I["Neuronal survival"]
D --> J["Impaired autophagy<br/>Protein aggregation"]
J --> K["Neurodegeneration"]
I -.->|protective| K
style A fill:#e3f2fd
style D fill:#fff3e0
style G fill:#e8f5e9
style K fill:#ffebee
PTPσ-mediated PI3P regulation affects:
- Autophagy flux — enhanced clearance of DPR proteins
- Endosomal trafficking — improved vesicle transport
- Synaptic function — preserved neuronal connectivity
- Protein homeostasis — reduced aggregation burden
PTPσ represents a novel therapeutic target for C9ORF72-ALS/FTD:
- Approach: Develop small molecule activators or positive allosteric modulators
- Challenge: Achieving brain penetration
- Advantage: Target validation from genetic screening
Potential combination approaches:
- PTPσ modulators + C9ORF72-targeting therapies
- PTPσ modulators + autophagy enhancers
- PTPσ modulators + antisense oligonucleotides